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Abstract
Sepsis still represents an important clinical and economic
challenge for intensive care units. Severe complications like multi-
organ failure with high mortality and the lack of specific diagnostic
tools continue to hamper the development of improved therapies
for sepsis. Fundamental questions regarding the cellular patho-
genesis of experimental and clinical sepsis remain unresolved.
According to experimental data, inhibiting macrophage migration
inhibitory factor, high-mobility group box protein 1 (HMGB1), and
complement factor C5a and inhibiting the TREM-1 (triggering
receptor expressed on myeloid cells 1) signaling pathway and
apoptosis represent promising new therapeutic options. In addition,
we have demonstrated that blocking the signal transduction
pathway of receptor of advanced glycation endproducts (RAGE), a
new inflammation-perpetuating receptor and a member of the
immunglobulin superfamily, increases survival in experimental
sepsis. The activation of RAGE by advanced glycation end-
products, S100, and HMGB1 initiates nuclear factor kappa B and
mitogen-activated protein kinase pathways. Importantly, the survival
rate of RAGE knockout mice was more than fourfold that of wild-
type mice in a septic shock model of cecal ligation and puncture
(CLP). Additionally, the application of soluble RAGE, an extra-
cellular decoy for RAGE ligands, improves survival in mice after
CLP, suggesting that RAGE is a central player in perpetuating the
innate immune response. Understanding the basic signal trans-
duction events triggered by this multi-ligand receptor may offer
new diagnostic and therapeutic options in patients with sepsis.
Introduction
In the United States, sepsis is the main cause of death in non-
cardiac intensive care units and is linked with increasing
costs for patient care. Sepsis represents a range of disorders
involving bacterial, fungal, or viral infections that can be
disseminated by the bloodstream [1]. Epidemiological data
from North America show an incidence of 3.0 cases per
1,000 persons. The overall mortality is approximately 50% in
patients with severe septic shock [2]. Even high-priority
engagement in sepsis research has led to only slight
improvements in existing treatment strategies for sepsis.
Currently, the detailed mechanisms linking the foreign
bacterial agent (for example, in the bloodstream or in the
abdomen) with the sophisticated ongoing transcription work
of the cell nucleus are not completely understood.
The combined use of the pre-existing innate and inducible
adaptive immune systems ensures that the host will be able
to mount an appropriate immune response against different
types of pathogenic agents [1]. The first line of defense is the
innate immune system, which is characterized by non-clonally
distributed leukocytes that react rapidly to microbial products
without antigenic specificity. Host innate responses to
bacterial or fungal infections are primarily mediated by neutro-
phils and monocytes/macrophages. These cells express
germline-encoded pattern-recognition receptors (PRRs),
which recognize certain invariable pathogen-associated
molecular patterns, or PAMPs, shared by groups of micro-
organisms. PRRs trigger signaling pathways that initiate an
inflammatory response to infection [3]. Activating isoforms
are truncated in their cytoplasmic tails and deliver stimulatory
signals by associating with transmembrane adapter proteins,
such as CD3γ, the γ-chain of Fc receptors, and DAP12 (also
Review
Bench-to-bedside review: The inflammation-perpetuating pattern-
recognition receptor RAGE as a therapeutic target in sepsis
Christian Bopp1, Angelika Bierhaus2, Stefan Hofer1, Axel Bouchon3, Peter P Nawroth2, 
Eike Martin1 and Markus A Weigand1
1Department of Anesthesiology, University of Heidelberg, Im Neuenheimer Feld 110, 69120 Heidelberg, Germany
2Department of Medicine I, University of Heidelberg, Im Neuenheimer Feld 410, 69120 Heidelberg, Germany
3Bayer CropScience, Alfred-Nobel-Str. 50, 40789 Monheim, Germany
Corresponding author: Markus A Weigand, markus.weigand@med.uni-heidelberg.de
Published: 9 January 2008 Critical Care 2008, 12:201 (doi:10.1186/cc6164)
This article is online at http://ccforum.com/content/12/1/201
© 2008 BioMed Central Ltd
AGE = advanced glycation endproduct; ALI = acute lung injury; CLP = cecal ligation and puncture; DTH = delayed-type hypersensitivity; EAE =
experimental allergic (or autoimmune) encephalomyelitis; EN-RAGE = extracellular newly identified receptor of advanced glycation endproducts-
binding protein; ERK-1/2 = extracellular signal-regulated kinase 1/2; HMGB1 = high-mobility group box protein 1; ICAM-1 = intercellular adhesion
molecule 1; IL = interleukin; JNK = c-jun N-terminal kinase; KO = knockout; LPS = lipopolysaccharide; MAPK = mitogen-activated protein kinase;
NF-κB = nuclear factor kappa B; PRR = pattern-recognition receptor; RAGE = receptor of advanced glycation endproducts; SAPK = stress-activated
protein kinase; sRAGE = soluble receptor of advanced glycation endproducts; TLR = Toll-like receptor; TNF = tumor necrosis factor; VCAM-1 = vascu-
lar cell adhesion molecule 1.Page 2 of 8
(page number not for citation purposes)
Critical Care    Vol 12 No 1 Bopp et al.
known as KARAP) [4]. Innate immune cells, however, also
receive continuous off signals via inhibitory receptors that
recognize ubiquitously expressed endogenous molecules.
These receptors transmit their inhibitory signals through a
cytoplasmatic immunoreceptor tyrosine-based inhibitory
motif, or ITIM [5].
The balance between activating and inhibitory signals gener-
ated by the engagement of these receptors ultimately controls
neutrophil- and macrophage-mediated phagocytosis, respira-
tory burst, and the release of proinflammatory cytokines. Under
certain circumstances, an excessive inflammatory response to
infectious agents can lead to septic shock. The disastrous
endpoint of an overstimulated immune system is multiple
organ failure as a result of endorgan damage. This process is
characterized by the massive release of proinflammatory
mediators such as tumor necrosis factor (TNF)-α, interleukin
(IL)-1, macrophage migration inhibitory factor, and high-
mobility group box protein 1 (HMGB1) [6,7].
The receptor of advanced glycation endproducts (RAGE), a
member of the immunglobulin superfamily, is involved in the
signal transduction from pathogen substrates to cell activation
during the onset and perpetuation of inflammation. Recent data
suggest (a) that RAGE perpetuates and amplifies inflammation
and (b) that targeting this receptor might attenuate
hyperinflammation. Therefore, this multi-ligand receptor should
be viewed as a PRR. Gaining further knowledge about the
ligands and basic mechanisms of this receptor may offer new
diagnostic and therapeutic options in patients with sepsis.
Receptor of advanced glycation endproducts
RAGE was first identified in lung tissue [8-10]. It is located
on the basolateral membranes of alveolar epithelial type I
cells [11], but RAGE mRNA has also been found in alveolar
epithelial type II cells [12]. Originally, RAGE was identified as
a receptor for advanced glycation endproducts (AGEs),
explaining the choice of this name. AGEs are products of
non-enzymatic glycation and oxidation of proteins, lipids, and
other macromolecules that appear, in particular, under
conditions of increased availability of reducing sugars and/or
enhanced oxidative stress, especially when molecules turn
over slowly and aldose levels are elevated [13,14].
RAGE expression occurs both constitutively and inducibly,
depending upon cell type and developmental stage. Whereas
RAGE is constitutively expressed during embryonal develop-
ment, RAGE expression is downregulated in adult life. Known
exceptions are skin and lung, which constitutively express
RAGE throughout life [15]. However, downregulated cells
can be induced to express RAGE in situations in which
inflammatory mediators and ligands accumulate [16,17]. The
activation of RAGE initiates nuclear factor kappa B (NF-κB)
[18,19] and mitogen-activated protein kinase (MAPK) path-
ways [20]. Additionally, RAGE-mediated cellular stimulation
promotes increased expression of the receptor itself. This
positive feedback loop, characterized by ligand-receptor
interaction followed by increased expression of the receptor,
suggests that RAGE functions as a propagation and
perpetuation factor: the two-hit model of RAGE engagement
is based on this finding [21]. The transcription factors
regulating RAGE in this setting include specificity protein-1,
activator protein-2, NF-κB, and NF-IL-6 [22]. Takada and
colleagues [23] reported that matrix metalloproteinase-9
(gelatinase B) plays a critical role in concordant expression,
at least in human pancreatic cancer cells.
Localization and structure of RAGE
The gene for RAGE is located on chromosome 6 near the
major histocompatibility complex III in humans and mice, in the
proximity of genes encoding TNF, lymphotoxin, and the
homebox gene HOX12 [24,25]. The extracellular domain of
RAGE consists of one V-type immunglobulin domain followed
by two C-type immunglobulin domains. The V-type domain, in
particular, interacts with the potential extracellular ligands
[9,10,19,20]. The rest of the molecule is a single trans-
membrane-spanning domain completed by a 43-amino acid,
highly charged cytosolic tail. This cytosolic tail lacks known
signaling motifs such as phosphorylation sites or kinase
domains. Hofmann and colleagues [26] showed that the
cytosolic tail is essential for signal transduction of RAGE
because a truncated form of RAGE, in which the cytosolic tail
is deleted, can bind both ligands and the wild-type receptor but
does not mediate any cellular activation. In the rat lung,
extracellular signal-regulated kinase 1/2 (ERK-1/2) was shown
to bind intracellularly to the cytoplasmic tail of RAGE,
suggesting that ERK may play a role in RAGE signaling
through interaction with RAGE [27]. The existence of truncated
and partly secreted RAGE isoforms from the same gene implies
that the pre-mRNA of RAGE in humans can be subjected to
alternative splicing [13]. In contrast, the truncated isoforms in
mice seem to be produced by carboxyl-terminal truncation [28].
Although only little is known about the physiologic role of
RAGE, it may fit with the concept of pleiotropic antagonism
[29]. This concept of an evolutionary basis for the develop-
ment of age-related diseases postulates that genes that are
beneficial during the reproductive phase of life may become
deleterious to development later on. Formerly, this interest
was mainly focused on the role of RAGE in chronic diseases.
Particularly under pathologic conditions, RAGE is up-
regulated in blood vessels, neurons, and transformed
epithelia and is involved in several chronic diseases, such as
rheumatoid arthritis, diabetes, inflammatory kidney disease,
arteriosclerosis, inflammatory bowel disease, neurodegener-
ative disorders (especially Alzheimer disease), and wound-
healing disorders [14].
RAGE interactions with its ligands in acute
inflammation and sepsis
RAGE is a multi-ligand receptor and interacts with different
structures to transmit a signal into the cell and recognizesPage 3 of 8
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three-dimensional structures rather than specific amino acid
sequences. Therefore, RAGE seems to fulfill the require-
ments of a PRR. As a member of the immunoglobulin super-
family, it interacts with a diverse class of ligands, including
AGEs [9,10], S100/calgranulins [26], HMGB1 [30], amyloid
β-peptide [31], amyloid A [32], leukocyte adhesion receptors
[33], prions [34], Escherichia coli curli operons [35], and
β-sheet fibrils [14].
The AGE-RAGE interaction
AGEs are a heterogeneous group of compounds produced
by non-enzymatic glycation and oxidation of proteins and
lipids that exhibit characteristic absorbance and fluorescence
properties,  Nε-(carboxymethyl)lysine being a highly reactive
AGE [36,37]. They are protease-resistant and can cause
irreversible tissue damage. AGEs can bind to various cellular
surface receptors and thereby induce post-receptor signal-
ing, activation of transcription factors, and gene expression in
vitro and in vivo. Several receptors that bind AGEs, including
AGE-R1, AGE-R2, AGE-R3, the scavenger receptor II, and
RAGE, have been identified [38]. Binding of AGEs (and other
ligands) to RAGE generates intracellular reactive oxygen
species and depletes antioxidant defense mechanisms at the
same time [39,40]. As a result, AGEs binding to RAGE,
reduced glutathione, and ascorbic acid are diminished.
Depletion of glutathione leads to reduced glyoxalase-1
recycling and decreased in situ activity. Glyoxalase-1,
however, has an important role in reducing the cellular AGE
load [38,41]. Furthermore, the myeloperoxidase in human
phagocytes generates Nε-(carboxymethyl)lysine at sites of
inflammation and thus sustains cellular activation via RAGE
[36]. AGE-RAGE interaction activates intracellular signal
transduction pathways, such as the ERK-1/2 kinases [27],
the p38 MAPK, the stress-activated protein kinase/c-jun N-
terminal kinase (SAPK/JNK) kinases [30,42], rho-GTPases,
phosphoinositide 3-kinases, JAK/STAT (Janus kinase/signal
transducer and activator of transcription) pathway [17,43,44],
and the NF-κB pathway [14] (Figure 1). In addition to
activating the NF-κB pathway, triggering RAGE induces de
novo p65 mRNA synthesis; this results in a growing pool of
transcriptionally active NF-κBp65, which appears to
overwhelm endogenous autoregulatory feedback inhibitory
loops [18]. However, no proximal signaling events directly
downstream of the receptor have been discovered yet. Only
direct binding of ERK to the intracellular domain of RAGE has
been demonstrated thus far [27].
NF-κB is frequently present in sepsis, hyperglycemia, and
oxidative stress. As already described, these conditions favor
formation of ‘advanced glycation endproducts’, which can
Available online http://ccforum.com/content/12/1/201
Figure 1
Receptor of advanced glycation endproducts (RAGE)-mediated signal transduction. AGE, advanced glycation endproduct; C, C-type
immunglobulin domain; ERK-1/2, extracellular signal-regulated kinase 1/2; HMGB1, high-mobility group box protein 1; ICAM-1, intercellular
adhesion molecule 1; IκB, inhibitor of kappa B; IKK, inhibitor of kappa B kinase; JAK, Janus kinase; JNK, c-jun N-terminal kinase; MAC-1,
macrophage-1 antigen; NF-κB, nuclear factor kappa B; P13K, phosphoinositide 3-kinase; ROS, reactive oxygen species; SAPK, stress-activated
protein kinase; STAT, signal transducer and activator of transcription; V, V-type immunglobulin domain; VCAM-1, vascular cell adhesion molecule 1;
VLA-4, very late antigen 4.trigger RAGE and subsequently lead to sustained inflam-
mation. Intensive insulin therapy interferes with this pathway
and therefore may explain, in part, why this treatment modality
is effective.
Relevance of RAGE-S100/calgranulin
interaction
In addition to binding AGEs, RAGE binds proteins of the
S100/calgranulin family, including S100-A12, also known as
extracellular newly identified RAGE-binding protein (EN-
RAGE), and S100B [18,26,45]. Most of the S100/
calgranulins are encoded on human chromosome 1q21 and
represent a family of multiple members that have important
intracellular properties that are linked to homeostatic
properties, such as calcium binding [46,47].
S100/calgranulin members such as S100A12 and S100B
activate endothelial cells, macrophages, smooth muscle cells,
and peripheral blood mononuclear cells (including T cells) via
RAGE, thus triggering activation of signaling cascades and
generation of cytokines and proinflammatory adhesion
molecules [26,48]. In addition, S100P stimulates cell prolifer-
ation and survival via RAGE [49]. However, whereas nano-
molar concentrations of S100B induce trophic effects in
RAGE-expressing cells, micromolar concentrations promote
apoptosis, likely through oxidant stress [50]. RAGE-S100
interactions have been implicated in inflammation, too, since
binding of S100A12 from the S100/calgranulin family to
RAGE in murine macrophages resulted in the elaboration of
IL-1β, TNF-α, and IL-2 [26]. Furthermore, EN-RAGE induced
intercellular adhesion molecule 1 (ICAM-1) and vascular cell
adhesion molecule 1 (VCAM-1) expression on endothelial
cells. EN-RAGE also decreased NF-κB activation and pro-
inflammatory cytokine expression by blocking RAGE engage-
ment. Intravenous infusion of EN-RAGE into mice enhanced
VCAM-1 expression in the lungs, which was abrogated by
soluble RAGE (sRAGE), neutralizing anti-EN-RAGE or anti-
RAGE monoclonal antibody and lending support to the in
vitro  findings. In addition, treatment with sRAGE in murine
models  in vivo strongly diminished delayed-type hyper-
sensitivity (DTH) and inflammatory colitis [26].
The precise mechanism by which transcription and translation
of S100/calgranulins are regulated is still poorly understood.
However, there is evidence that these molecules are released
by activated monocytes, promoting the presence of
S100/calgranulin at sites of inflammation [26,47]. Interaction
of these polypeptides and RAGE, therefore, might represent a
proximal step in the cascade of events perpetuating
inflammation. We [51] demonstrated that S100 species are
increased in septic patients. However, we did not observe any
significant difference between survivors and non-survivors.
Amphoterin/HMGB1 as RAGE ligand
Amphoterin, one of the HMGB DNA-binding proteins
(amphoterin is another name for HMGB1), also acts as a
signal-transducing ligand of RAGE. HMGB1, encoded on
human chromosome 13q12-13, is a nuclear protein present
in almost all eukaryotic cells. It stabilizes nucleosome function
and acts as a transcription factor-like protein that regulates
the expression of several genes [52]. The non-histone
chromosomal protein HMGB1 not only has intracellular
functions, but also may exist extracellularly and on the surface
of cells, especially on migrating cells in neuronal development
and tumors [43,53,54]. It is secreted as a cytokine by
activated macrophages, mature dendritic cells, and natural
killer cells in response to cell stimulation [55]. Active release
is observed after acetylation in the nucleus, blocking re-entry
into the nucleus by interacting with the nuclear-importer
protein complex [56]. Thereafter, cytosolic HMGB1 migrates
to cytoplasmic secretory vesicles, where it is released into the
immunological synapse or into the extracellular space.
Together with S100 [26], heat shock proteins [57], ATP [58],
and uric acid [59], HMGB1 [60] is one of the main
prototypes of the group of so-called damage-associated
molecular pattern molecules: all of these molecules are
released in response to infection or other inflammatory
stimuli, especially during tissue damage (for example, by
necrotic cells). Whereas HMGB1 is released from the
nucleus, the other molecules are localized in the cytosol.
Cellular migration, invasion, and proliferation are enhanced
when RAGE is engaged in tumor cells via HMGB1 [43]. A
COOH-terminal motif in HMGB1 (amino acids 150 to 183)
seems to be responsible for RAGE binding [61]. HMGB1
has a propagating role in inflammatory responses [6,62] and
seems to be an important RAGE ligand in sepsis and acute
inflammation [52,63,64]. Recent studies have shown that the
monocyte-derived HMGB1 is a late-acting cytokine mediator
of endotoxin lethality. In animal experiments, the time-
dependent induction of HMGB1 release by macrophage
cultures could be detected 8 hours after lipopolysaccharide
(LPS) stimulation. Furthermore, endotoxemia leads to a
systemic increase in HMGB1 levels in mice [6,64]. Systemic
HMGB1 levels were also measured during endotoxemia in
the serum of mice after injection of LPS. HMGB1 was first
detected in serum after 8 hours and increased to a plateau
from 16 to 32 hours after LPS stimulation [6]. Interestingly,
this delay is one of the typical observations in patients with
sepsis, when clinical signs appear several hours after the first
infection-associated cytokines are detected in the blood-
stream, and opens a therapeutic window. Examinations in
healthy volunteers and septic patients showed (a) no
HMGB1 in the serum of healthy humans, (b) dramatically
increased HMGB1 levels in septic patients, and (c) markedly
higher HMGB1 levels in non-survivors of septic shock than in
patients who survived [6].
HMGB1 amplifies the cytokine cascade during systemic
inflammation [62,64]. In addition, HMGB1 seems to be an
autocrine/paracrine regulator of monocyte invasion, involving
RAGE through the endothelium [65]. The proinflammatory
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When this HMGB1 B-box was added to enterocytic mono-
layers, intenstinal permeability increased [66]. These effects
were strongly diminished in the presence of an anti-RAGE
antibody, suggesting a significant role of RAGE in HMGB1-
initiated pathogenic events. Using bone marrow macro-
phages from RAGE knockout (KO) mice, Kokkola and
colleagues [67] recently provided formal proof that a major
component of HMGB1 action on cells is mediated via RAGE.
As a response to HMGB1 stimulation, macrophages from
RAGE KO mice produced significantly lower amounts of
TNF, IL-1β, and IL-6. However, cytokine production was not
totally abrogated in RAGE–/– macrophages, although there
was a significant difference from that of wild-type
macrophages. In addition, phosphorylation of p38, p44/42, or
SAPK/JNK kinases was similar to that of wild-type
macrophages and macrophages from IL-1 RI KO mice. These
data clearly indicate that RAGE is a major receptor for
HMGB1 but that HMGB1 also exerts important effects via
different receptors such as Toll-like receptor (TLR)-2 and
TLR-4 [68].
Park and colleagues [68] showed that interactions of
HMGB1 with TLR-2 and TLR-4 represent early events after
macrophage exposure to HMGB1. In contrast, they found
only scant evidence of binding between HMGB1 and RAGE
in their experiments. Recently, Yu and colleagues [69]
demonstrated that neutralizing antibodies against TLR-4, but
not TLR-2 or RAGE, dose-dependently attenuated HMGB1-
induced IL-8 release in human whole blood. The interaction of
HMGB1 and TLR-4 seems to be important in liver ischemia/
reperfusion also [70]. Interestingly, the N-terminal domain of
thrombomodulin sequesters HMGB1, preventing HMGB1
from binding to RAGE [63]. Furthermore, a soluble form of
this N-terminal domain of thrombomodulin protected mice
from LPS-induced lethal shock. This survival benefit was
observed in both wild-type and RAGE KO mice. Importantly,
lethality in RAGE KO mice was only 50%, as compared with
100% in wild-type mice, after administration of a high dose of
LPS. Neutralizing HMGB1 reduced the lethality in RAGE KO
mice to zero, further confirming that HMGB1 exerts its
deleterious effects not only via RAGE.
In vivo, administration of blocking antibodies to HMGB1
resulted in an improved survival in rodents subjected to high-
dose LPS [6]. In an animal model of LPS-induced acute lung
injury (ALI), the administration of anti-HMGB1, notably both
before and after endotoxin administration, reduced the typical
signs of lung damage in acute inflammation, such as
neutrophil accumulation and lung edema [71]. These results
were supported by Ueno and colleagues [72], who found that
concentrations of HMGB1 were increased in plasma and
lung epithelial lining fluid of patients with ALI. Extracellular
HMGB1 may play a key role in the pathogenesis of clinical
and experimental ALI. However, it is also expressed in healthy
airways, which suggests that it plays a physiologic role in the
lung as well [72]. Data have shown that anti-HMGB1 anti-
bodies protect against sepsis in an animal model of cecal
ligation and puncture (CLP), even when antibody adminis-
tration is delayed by 24 hours [73]. These studies indicate that
anti-HMGB1 antiserum may be a new, potential therapeutic
target, as survival improved greatly in LPS- and CLP-treated
mice [6,73]. The observation that administration of blocking
antibodies to HMGB1 protected mice from lethal septicemia
strongly suggests that the engagement of cell surface
receptors such as RAGE by HMGB1 might play an important
role in mediating the pathogenic effects of HMGB1 [6].
Wang and colleagues [74] demonstrated that nicotinic
stimulation prevents activation of the NF-κB pathway and
inhibits HMGB1 secretion through a specific nicotinic anti-
inflammatory pathway. In conclusion, acetylcholine seems to
be the first known inhibitor of HMGB1 released from human
macrophages. Nevertheless, it has not yet been formally
proven that direct interaction of HMGB1-RAGE contributes
to sepsis lethality, and other interactions such as HMGB1-
TLR-2 and -TLR-4 are also important.
Potential clinical perspectives
Engagement of RAGE by its ligands results in sustained NF-κB
activation [14] in all cell types studied so far, particularly
mononuclear phagocytes and vascular endothelium [75].
Sustained cellular activation leads to cellular dysfunction and
tissue destruction. When sRAGE used as a decoy, RAGE-
neutralizing antibodies, and a dominant-negative receptor
have been used, RAGE has been shown to be involved in
different chronic disease models.
RAGE also has a critical role in acute inflammation. A
resulting deleterious inflammatory response after ischemia/
reperfusion of the liver has been associated with RAGE
engagement in mice. The problem of ischemia/reperfusion is
clinically relevant for liver transplantion or resection. In an
animal model of total hepatic ischemia, blocking RAGE by
administering sRAGE increased survival and caused fewer
histological alterations in treated animals, which is in line with
a decrease in RAGE-induced signaling and activation of
transcription factors [76]. Furthermore, blocking RAGE signifi-
cantly increased survival after massive liver resection [77].
We have clarified the role of RAGE in sepsis, DTH, and
autoimmune encephalomyelitis (EAE) [75]. Several studies
investigating the role of RAGE in inflammatory diseases used
sRAGE to bind extracellulary potential RAGE ligands
[26,43,78]. However, not only does sRAGE scavenge the
ligands and prevent them from interacting with RAGE, but
these ligands may be able to engage further receptor types
and transduce completely different signaling pathways. To
overcome this problem, RAGE KO mice were studied. In the
setting of EAE, which served as a model to test the role of
RAGE in the adaptive immune response, no differences
between wild-type and RAGE KO mice could be detected
Available online http://ccforum.com/content/12/1/201
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significantly enhanced clinical EAE scores. In addition, RAGE
KO mice and wild-type species developed the same
inflammatory response in a second model (DTH). At first
glance, these results seemed to be in contrast to previous
data from DTH experiments with sRAGE, in which the
inflammatory response in mice pretreated with sRAGE was
lower [26]. The application of sRAGE in wild-type and RAGE
KO mice, however, reduced the inflammatory response in
mice in the DTH model [75]. These findings support the
concept that the effects of sRAGE in DTH were not caused
mainly by preventing ligand engagement of the cell-bound
RAGE [75]. Thus, RAGE ligands exert their effects in these
diseases through different receptors. Likely candidates to
bind one or more of these ligands are known AGE receptors
AGE-R1, AGE-R2, AGE-R3, and CD36 as well as newly
identified AGE-binding proteins such as N-glycans, ezrin, and
megalin [14].
In contrast to the minor role of RAGE in adaptive immunity,
the most interesting finding was that RAGE KO mice were
protected from lethal septic shock as compared with wild-
type controls. In a CLP model, largely dependent on the
innate immune response, RAGE KO mice were also better
protected from lethal septic shock than were wild-type
controls (80% versus 20%). To confirm the critical role of
RAGE in sepsis and to exclude artifacts by gene deletion,
RAGE KO mice were crossed into tie2-RAGE mice
overexpressing RAGE in the vasculature. Mortality in these
mice was similar to that in wild-type mice.
To test whether blocking of RAGE signaling pathways by
sRAGE might be a therapeutic option, we injected sRAGE
into wild-type mice, which resulted in an improved survival
(40% versus 17%) compared with untreated control animals.
NF-κB activation was more strongly induced in lungs of wild-
type mice than in RAGE KO mice, suggesting a main
contributing role in reducing mortality in RAGE KO mice and
one that fits the high RAGE expression in the lung. In
conclusion, these findings show that RAGE KO mice have, at
least in part, a normal adaptive immune system. In contrast,
the PRR RAGE displays a central role in the innate immune
system, with an impact on perpetuation of the immune
response [75].
In addition, we found that RAGE serves as a novel counter-
receptor for the leukocyte β2 integrin Mac-1 (CD11b/CD18)
and (to a lesser extent) p150,95 (CD11c/CD18), being
directly involved in leukocyte recruitment in vitro and in vivo
[33]. This leukocyte recruitment via RAGE is enhanced in the
presence of S100 proteins. Thus, RAGE acts as an
endothelial adhesion receptor, promoting leukocyte recruit-
ment and subsequent inflammation by direct binding of
leukocytes, and enhances expression of VCAM-1 and ICAM-1
after engagement of RAGE [14,26]. These findings are
consistent with the fact that histological examination showed
fewer inflammatory cells adherent to the peritoneum of RAGE
KO mice after CLP as compared with that of wild-type mice
[75]. Remarkably, RAGE–/– seems to have a moderate
proinflammatory phenotype because C-reactive protein, basal
NF-κB activation, and cytokine levels were slightly increased.
In conclusion, the crucial role of RAGE in experimental sepsis
not only provides strong evidence for its perpetuating role in
the innate immune response, but may open further oppor-
tunities to develop novel approaches for treating septicemia.
A number of studies, including clinical investigations, have
shown that genetic variants of RAGE might be of further
interest [79,80]. These variants are found on coding/
translational sequences as well as in the transcriptional
regulatory elements. Hofmann and colleagues [81] found that
the variant form of RAGE enhances binding and cytokine
production compared with wild-type animals. What kind of
cellular consequences these genetic polymorphisms have
and what clinical relevance these polymorphisms will have
remain to be determined in further studies.
Conclusion
This review summarizes the current knowledge on RAGE, a
new inflammation-perpetuating receptor, which plays a pivotal
role in sepsis. It is involved in signal transduction from
pathogen substrates to cell activation during the onset of
inflammation and perpetuates the immune response.
Targeting this receptor might attenuate hyperinflammation.
Essentially, understanding the basic signal transduction of
RAGE may offer new diagnostic and therapeutic options in
patients with sepsis.
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